bf/NASDAQ:INKT_icon.jpeg

NASDAQ:INKT

MiNK Therapeutics, Inc.

  • Stock

USD

Last Close

13.66

06/11 21:00

Market Cap

30.21M

Beta: -

Volume Today

858

Avg: 87.89K

PE Ratio

0.21

PFCF: −1.71

OverviewFinancialsAPI

    Description

    MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.6-0.5-0.4-0.3-0.2-0.12020-03-302020-12-312022-03-182023-08-102024-08-082025-11-12

    Revenue (Estimate*)

    500M1B1.50B2B2.50B2020-03-302020-12-312022-03-182023-08-102024-08-082025-11-12

    *Estimate based on analyst consensus